Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Factbox: AstraZeneca's potential coronavirus vaccine

share with twitter share with LinkedIn share with facebook
09/01/2020 | 09:47am EDT
FILE PHOTO: A man walks past a sign at an AstraZeneca site in Macclesfield

AstraZeneca has expanded its agreement with Oxford Biomedica to mass-produce its COVID-19 potential vaccine, the cell therapy firm said on Tuesday.

Drugmakers are racing to combat the pandemic, which has killed more than 850,000 people and infected over 25 million.

There are no approved vaccines for COVID-19, but AstraZeneca's vaccine is widely seen as one of the leading candidates, with reports that the United States is aiming for a fast-track approval before the November presidential election.

The company has been granted protection from future product liability claims related to the vaccine by most of the countries with which it has so far struck supply agreements, a senior executive told Reuters.

Below are the main details of the vaccine and its supply and production deals.


** The shot, called AZD1222 or ChAdOx1 nCoV-19, is a recombinant viral vector vaccine developed by the University of Oxford.

** It was licensed to AstraZeneca in April.

** The vaccine candidate uses a weakened version of a chimpanzee common-cold virus that encodes instructions for making proteins from the novel coronavirus to build immunity.


** The shot is likely to provide protection for about a year, and the company is leaning towards a two-dose strategy for the potential vaccine.


** AstraZeneca says it will be able to manufacture the vaccine at a few dollars per dose.

** Pricing in Latin America, while still not final, is not expected to exceed $4 per dose, said AstraZeneca's Mexico head.

** India's Serum Institute said it will price the shot at $3 per dose for the country and other emerging economies.

** According to Italy's health ministry, an AZD1222 shot would cost about 2.5 euros ($2.8) per dose in Europe.

** AstraZeneca does not expect to profit from the vaccine candidate during the pandemic.

** Costs in other regions have not been disclosed.


** AstraZeneca said on Monday it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of the vaccine.

** AstraZeneca's CEO said good data had come in so far on the vaccine, after early-stage trials showed it was safe and produced an immune response.

** Trials at different stages are underway in Britain, Brazil, South Africa, United States and India. Trials are planned in Japan and Russia as well.

** Talks are ongoing with Mexico, and a smaller early-stage study is being conducted in South Africa to see how the vaccine works in those with HIV.


** Data could be given to regulators this year.

** The vaccine could be rolled out by year-end, but there is no certainty of that, the lead developer said in July.

** Data from late-stage studies is expected around September.

** Delivery of the first doses is expected between September and October.

** Experts have predicted a safe and effective vaccine could take 12-18 months to develop.


** 3 billion.


** Even before conclusive evidence of the vaccine's success or failure, AstraZeneca has signed deals to produce and supply the shot. With U.S. backing, the company also tied up with IQVIA in July to speed up trials.

(Reporting by Pushkala Aripaka in Bengaluru; Additional reporting by Tanishaa Nadkar; Editing by Jan Harvey, Mark Potter and Louise Heavens)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.40% 7766 Delayed Quote.2.09%
DOW JONES AFRICA TITANS 50 INDEX 1.20% 469.73 Delayed Quote.-12.38%
DOW JONES SOUTH AFRICA(ZAR) 0.07% 1598.89 Delayed Quote.-11.38%
EURO / BRAZILIAN REAL (EUR/BRL) -0.87% 6.6872 Delayed Quote.49.72%
IQVIA HOLDINGS INC. -0.43% 153.99 Delayed Quote.-0.34%
OXFORD BIOMEDICA PLC -1.47% 804 Delayed Quote.24.65%
S&P AFRICA 40 INDEX 0.89% 154.11 Delayed Quote.-11.58%
UNITED PARCEL SERVICE, INC. -2.63% 157.11 Delayed Quote.34.21%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) -0.05% 79.431 Delayed Quote.27.02%
share with twitter share with LinkedIn share with facebook
Latest news "Companies"
06:37pDUKE ENERGY : restores power to nearly 90% of Carolinas customers who lost electricity due to Tropical Storm Zeta
06:30pTACTILE TECHNOLOGY : ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds Tactile Systems Technology, Inc. Investors of Important November 30 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - TCMD
06:25p6 P.M. UPDATE : Georgia Power working to restore remaining 55,000 customers after Hurricane Zeta
06:20pNIKOLA : ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Nikola Corporation Investors of Important November 16 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $500K to Contact the Firm - NKLA, NKLAW, VTIQ, VTIQW, VTIQU
06:15pMemorandum on Protecting Jobs, Economic Opportunities, and National Security for All Americans
06:15pPresident Donald J. Trump Is Supporting Hydraulic Fracturing and Other Technologies to Protect Our Jobs, Economic Opportunity, and National Security
06:15pTHOUGHTFUL BRANDS : Provides Update on Verrian and Announces New CFO
06:15pDUKE ENERGY : restores power to nearly 90% of Carolinas customers who lost electricity due to Tropical Storm Zeta
06:00pNational veteran business development council announces live entertainment for vets night out
05:12pAMAZON COM : drops French Black Friday ad campaign as lockdown starts
Latest news "Companies"